AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Learn more →

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer

Phase 3

Active, not recruiting

Conditions: Non-muscle-invasive Bladder Cancer

Interventions: Biological: Durvalumab (MEDI4736)
Biological: Bacillus Calmette-Guerin (BCG)

First Posted Date: 2018-05-18

Last Posted Date: 2025-05-11

Lead Sponsor: AstraZeneca

Target Recruit Count: 1018

Registration Number: NCT03528694

Locations: 🇬🇧
Research Site, Taunton, United Kingdom

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

Phase 3

Active, not recruiting

Conditions: Non Small Cell Lung Cancer (Stage III)

Interventions: Drug: Osimertinib 80mg/40mg
Drug: Placebo Osimertinib 80mg/40mg

First Posted Date: 2018-05-11

Last Posted Date: 2025-04-03

Lead Sponsor: AstraZeneca

Target Recruit Count: 216

Registration Number: NCT03521154

Locations: 🇻🇳
Research Site, Ho Chi Minh, Vietnam

Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

Phase 3

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Durvalumab
Other: Placebo
Drug: Cisplatin/ Etoposide
Drug: Carboplatin/ Paclitaxel
Drug: Pemetrexed/ Cisplatin
Drug: Pemetrexed/ Carboplatin
Radiation: Radiation

First Posted Date: 2018-05-09

Last Posted Date: 2025-04-08

Lead Sponsor: AstraZeneca

Target Recruit Count: 328

Registration Number: NCT03519971

Locations: 🇻🇳
Research Site, Ho Chi Minh, Vietnam

Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong

Withdrawn

Conditions: Non-small Cell Lung Cancer

Interventions: Diagnostic Test: Plasma-tissue testing

First Posted Date: 2018-05-09

Last Posted Date: 2018-11-16

Lead Sponsor: AstraZeneca

Registration Number: NCT03519958

Prospective Tissue Collection Research Protocol

Completed

Conditions: Solid Tumor

Interventions: Other: Tumour tissue collection

First Posted Date: 2018-05-08

Last Posted Date: 2025-05-23

Lead Sponsor: AstraZeneca

Target Recruit Count: 221

Registration Number: NCT03517917

Locations: 🇬🇧
Research Site, Uxbridge, United Kingdom

Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Carcinoma, Squamous Cell of Head and Neck
Carcinoma, Non-Small-Cell Lung
Small Cell Lung Carcinoma

Interventions: Drug: Durvalumab
Drug: Cisplatin (dose level 4)
Drug: Etoposide (dose level 1)
Drug: Carboplatin (dose level 1)
Drug: Cisplatin (dose level 3)
Drug: Tremelimumab
Drug: Carboplatin (dose level 2)
Radiation: External beam radiation (dose level 1)
Drug: Pemetrexed
Drug: Paclitaxel
Drug: Etoposide (dose level 2)
Drug: Cisplatin (dose level 1)
Radiation: External beam radiation (dose level 2)
Drug: Cisplatin (dose level 2)
Radiation: External beam radiation (standard)
Radiation: External beam radiation (hyperfractionated)

First Posted Date: 2018-04-26

Last Posted Date: 2025-01-14

Lead Sponsor: AstraZeneca

Target Recruit Count: 105

Registration Number: NCT03509012

Locations: 🇨🇳
Research Site, Taoyuan City, Taiwan

Lynparza Ovarian Cancer Clinical Experience Investigation (All Case Investigation)

Completed

Conditions: Ovarian Cancer

First Posted Date: 2018-04-23

Last Posted Date: 2022-06-01

Lead Sponsor: AstraZeneca

Target Recruit Count: 846

Registration Number: NCT03505307

An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia

Conditions: Relapsed/Refractory Hairy Cell Leukemia

First Posted Date: 2018-04-18

Last Posted Date: 2020-06-29

Lead Sponsor: AstraZeneca

Registration Number: NCT03501615

PK Study of Ticagrelor in Children Aged Less Than 24 Months, With Sickle Cell Disease (HESTIA4)

Phase 1

Completed

Conditions: Sickle Cell Disease

Interventions: Drug: Ticagrelor

First Posted Date: 2018-04-10

Last Posted Date: 2021-05-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 21

Registration Number: NCT03492931

Locations: 🇬🇧
Research Site, London, United Kingdom

Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors
Pancreatic Cancer
Non Small Cell Lung Cancer
Ovarian Cancer

Interventions: Biological: MSC-1

First Posted Date: 2018-04-06

Last Posted Date: 2024-04-05

Lead Sponsor: AstraZeneca

Target Recruit Count: 41

Registration Number: NCT03490669

Locations: 🇨🇦
Princess Margaret Cancer Center, Toronto, Ontario, Canada
🇪🇸
Hospital Universitario Vall d'Hebron, Barcelona, Spain
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 4 locations

Home Terms & Conditions Privacy Policy